Previous 10 | Next 10 |
As the first-ever U.S. Food and Drug Administration (FDA) approved over-the-counter (OTC) naloxone in 2023, Emergent is working to expand access with NARCAN ® Nasal Spray and build on its longstanding efforts with public interest entities across the country Hundreds of thousands...
2024-03-25 08:54:44 ET More on Emergent Biosolutions Emergent BioSolutions Inc. (EBS) Q4 2023 Earnings Call Transcript Emergent BioSolutions Inc. 2023 Q4 - Results - Earnings Call Presentation New CEO Appointment A Clear Positive For Emergent BioSolutions Ben...
GAITHERSBURG, Md., March 25, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has listed “No Action Indicated” or NAI status classification for the company's Baltimore Bayview manufacturing facility. Base...
2024-03-07 11:36:09 ET More on Emergent Biosolutions New CEO Appointment A Clear Positive For Emergent BioSolutions Emergent Biosolutions Q4 2023 Earnings Preview Emergent surges 66% as it brings in Bausch + Lomb vet Papa as CEO Read the full article on See...
2024-03-07 10:01:04 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Waters, Moderna most shorted ...
2024-03-07 08:35:57 ET More on Pre-market losers & stocks. Rail Vision shares rally as Main Line System gets EU approval and certifications Rail Vision wins contract valued at up to $5 million, shares jump Financial information for Airship AI Holdings, Inc. ...
2024-03-06 23:30:14 ET Image source: The Motley Fool. Emergent BioSolutions (NYSE: EBS) Q4 2023 Earnings Call Mar 06, 2024 , 5:00 p.m. ET Operator Continue reading For further details see: Emergent BioSolutions (EBS) Q4 2023 Earnings Call Tran...
2024-03-06 19:37:26 ET Emergent BioSolutions Inc. (EBS) Q4 2023 Earnings Conference Call March 06, 2024, 05:00 PM ET Company Participants Rich Lindahl - Executive Vice President & Chief Financial Officer Joe Papa - President and Chief Executive Officer Paul W...
2024-03-06 16:50:48 ET More on Emergent Biosolutions New CEO Appointment A Clear Positive For Emergent BioSolutions Emergent BioSolutions: Q3 Numbers Leave Work To Be Done Emergent Biosolutions Q4 2023 Earnings Preview Emergent surges 66% as it brings in Baus...
Fourth Quarter 2023 Total Revenues of $277 million, which aligned our Full Year to the mid-point of guidance Full Year 2023 Total Revenues of $1.05 billion, which was the mid-point of guidance Fourth Quarter 2023 Net Loss of $50 million and Adjusted EBITDA of $3 million Issues Q1...
News, Short Squeeze, Breakout and More Instantly...
Emergent Biosolutions Inc. Company Name:
EBS Stock Symbol:
NYSE Market:
Emergent Biosolutions Inc. Website:
New video and radio segments raise awareness of a potentially life-saving, three-step method that anyone can use to respond in a suspected opioid poisoning GAITHERSBURG, Md., July 24, 2024 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions Inc. (NYSE: EBS) announced the launch of a new opio...
GAITHERSBURG, Md., July 23, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, August 6, 2024, at 5:00 pm eastern time to discuss the financial results for the second quarter 2024, key business updates, revenue guidance for the third quarter of...
The extension to a four-year shelf-life helps improve naloxone access as communities continue to grapple with the growing opioid epidemic; product with the extended shelf life has officially begun shipping WINNIPEG, Manitoba, July 22, 2024 (GLOBE NEWSWIRE) -- Today, Emergent BioSolution...